Peter A. Friedli

Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD.

Invenda Corp. provides interactive marketing technologies and services via the Internet. Its business units include mtbr.com, roadbikereview.com, media kit, e-centives and collabrys. The company was founded by Kamran Amjadi and Peter A. Friedli in 1996 and is headquartered in Bethesda, MD.

New Venturetec AG is an investment and holding company, which engages in holding a direct and indirect investments in the biotechnology companies. It also obtains capital appreciation from well-selected companies that are at the forefront of the technology and products. The company was founded by Peter A. Friedli on July 16, 1997 and is headquartered in Zug, Switzerland.

Inflabloc Pharmaceuticals, Inc. engages in the research and development of pharmaceutical treatments. It develops products for the treatment of gastrointestinal disorders and inflammatory diseases. The company was founded in 1991 and is headquartered in Salt Lake City, UT.

Vertical Circuits Inc. is a global supplier of advanced die level vertical interconnect packaging technology, products, services and intellectual property for the manufacture of low-cost, ultra high-speed/high-density semiconductor components. They develop cost effective advanced interconnect technology for high density and high performance applications. Its patented ViP™ (vertical interconnect pillar) process bridges the gap between current wire bond based product solutions and tomorrow's through silicon via technology. They enable packaging solutions for Memory and Mixed Die applications including a broad range of server, networking & handheld portable consumer electronics systems products.

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

mPortal, Inc. designs and develops mobile content and applications. Its mobile network operators, moble virtual network operators, cable operators, content providers, and business enterprises. The company was founded in 2000 and is headquartered in McLean, VA.

Friedli Corporate Finance AG (Friedli CF) is a venture capital holding and management firm established in 1986 and based in Zurich. The firm manages the Venturetec funds as well as a portfolio of private equity participations, through Madison Partners SA which is their New York-based subsidiary. Madison Partners is controlled by Peter Friedli and the minority shareholder is Kevin Kimberlin, the chairman of the venture capital firm Spencer Trask & Co. Friedli CF's investors include banks, pension funds and corporations, primarily based in Switzerland.